India's first dengue vaccine arrives with a crucial safety caveat
Practice PYQs on this topic
500+ questions on Science & Tech with explanations
📌 Summary:
-
India's drug regulator has approved the country's FIRST dengue vaccine, Qdenga, designed to protect against all four dengue serotypes (DENV-1 to DENV-4)
-
It is approved for children and adults aged 4-60 years, irrespective of whether they have had dengue before
-
Qdenga is manufactured by the Japanese pharmaceutical company Takeda and has already been approved in more than 40 countries
-
Safety caveat: clinical-trial data (published 2019, 2020 and 2024) raise a specific concern — protection against certain serotypes (notably DENV-3) is weaker in people never previously infected (seronegative), raising a theoretical antibody-enhancement risk, which is why pre-vaccination screening and monitoring matter
🎯 UPSC Relevance: GS3 S&T + GS2 Health — vaccine approval and regulation, public-health policy, vector-borne disease control and biotechnology.
📝 Prelims Facts:
- Qdenga (TAK-003) is made by Takeda (Japan); it targets all four serotypes DENV-1 to DENV-4
- Approved age band in India: 4-60 years; it is India's FIRST dengue vaccine
- Dengue is caused by a flavivirus and transmitted by the Aedes aegypti mosquito
🔑 Key Term: Serotype — a distinct antigenic variant within a virus species; dengue has four serotypes (DENV-1 to DENV-4), and infection by one confers only limited, temporary cross-protection against the others.
UPSC Classification
See PYQs related to “Science & Tech”
Every classification tag above links to actual UPSC questions asked on that topic — with answer, explanation and elimination logic. Only in the app.